๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Cryosurgical ablation of the prostate : High-risk patient outcomes

โœ Scribed by Kristofer L. Prepelica; Zephaniah Okeke; Alana Murphy; Aaron E. Katz

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
109 KB
Volume
103
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Long-term outcomes after treatment with
Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features
โœ Michael Dattoli; Kent Wallner; Lawrence True; Jennifer Cash; Richard Sorace ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 236 KB

## Abstract ## BACKGROUND. This study summarizes longโ€term outcomes from treatment of prostate cancer with increased risk of extracapsular cancer extension (ECE) using brachytherapyโ€based treatment. ## METHODS. A total of 282 consecutive patients were treated from 1992โ€“1996 by 1 author (M.D.). T

Five-year clinical outcomes of sirolimus
Five-year clinical outcomes of sirolimus-eluting versus paclitaxel-eluting stents in high-risk patients
โœ K. Anette Birkmeier; Adnan Kastrati; Robert A. Byrne; Heidrun Holle; Stefanie Sc ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 336 KB ๐Ÿ‘ 2 views

## Abstract Objectives and Background: First generation drugโ€eluting stents have shown differential efficacy in highโ€risk patient subsets at one year. It is unclear whether these differences endure over the mediumโ€ to longโ€term. We compared the fiveโ€year clinical efficacy and safety of sirolimusโ€el

Correlation of molecular human leukocyte
Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon
โœ Helen Gogas; John M. Kirkwood; Christine S. Falk; Urania Dafni; Vernon K. Sondak ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 226 KB

## Abstract ## BACKGROUND: Interferon is approved for adjuvant treatment of patients with stage IIB/III melanoma. The identification of predictive markers that would permit selection of patients would be beneficial. Specific human leukocyte antigen (HLA) class I and II antigens have previously sho